PCSK9 and infection

A potentially useful or dangerous association?

Farzad Khademi, Amir Abbas Momtazi-borojeni, Željko Reiner, Maciej Banach, Khalid Al Al-Rasadi, Amirhossein Sahebkar

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Elevated plasma low-density lipoprotein-cholesterol (LDL-C) concentration is the most important risk factor for atherosclerotic cardiovascular diseases (CVDs). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ubiquitously expressed serine proteinase which plays a key role in cholesterol metabolism, but has been found to be implicated in some other lipid-independent physiological processes. In this review, the role of PCSK9 was evaluated not only concerning lipid metabolism but also hepatitis C virus (HCV) infection, bacterial infections/sepsis, and septic shock. Collected data from clinical trials revealed that treatment with PCSK9 inhibitors has beneficial effects in lowering LDL-C via inhibition of LDL-receptors (LDL-R), an antiviral effect on HCV infection via down-regulating the surface expression of LDL-R and CD81 on hepatic cells, and a positive association with increased inflammatory responses, as well as with septic shock by down-regulation of hepatocyte LDL-R. On the other hand, PCSK9 inhibition by therapeutic fully humanized antibodies has positive effects in reducing elevated LDL-C. However, their safety and tolerability is an important issue which has to be taken into consideration.

Original languageEnglish
JournalJournal of Cellular Physiology
DOIs
Publication statusAccepted/In press - 2017

Fingerprint

Proprotein Convertases
Subtilisin
LDL Receptors
Virus Diseases
Septic Shock
Infection
Hepacivirus
LDL Cholesterol
Hepatocytes
Physiological Phenomena
Antibodies, Monoclonal, Humanized
Bacteriophages
Serine Proteases
Viruses
Lipid Metabolism
Bacterial Infections
Metabolism
Antiviral Agents
Sepsis
Cardiovascular Diseases

Keywords

  • Cholesterol
  • Hepatitis C virus
  • Infection
  • LDL receptor
  • PCSK9

ASJC Scopus subject areas

  • Medicine(all)
  • Physiology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Khademi, F., Momtazi-borojeni, A. A., Reiner, Ž., Banach, M., Al-Rasadi, K. A., & Sahebkar, A. (Accepted/In press). PCSK9 and infection: A potentially useful or dangerous association? Journal of Cellular Physiology. https://doi.org/10.1002/jcp.26040

PCSK9 and infection : A potentially useful or dangerous association? / Khademi, Farzad; Momtazi-borojeni, Amir Abbas; Reiner, Željko; Banach, Maciej; Al-Rasadi, Khalid Al; Sahebkar, Amirhossein.

In: Journal of Cellular Physiology, 2017.

Research output: Contribution to journalArticle

Khademi, Farzad ; Momtazi-borojeni, Amir Abbas ; Reiner, Željko ; Banach, Maciej ; Al-Rasadi, Khalid Al ; Sahebkar, Amirhossein. / PCSK9 and infection : A potentially useful or dangerous association?. In: Journal of Cellular Physiology. 2017.
@article{a60ef79b7a5a40b5a31df6c287ffa86a,
title = "PCSK9 and infection: A potentially useful or dangerous association?",
abstract = "Elevated plasma low-density lipoprotein-cholesterol (LDL-C) concentration is the most important risk factor for atherosclerotic cardiovascular diseases (CVDs). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ubiquitously expressed serine proteinase which plays a key role in cholesterol metabolism, but has been found to be implicated in some other lipid-independent physiological processes. In this review, the role of PCSK9 was evaluated not only concerning lipid metabolism but also hepatitis C virus (HCV) infection, bacterial infections/sepsis, and septic shock. Collected data from clinical trials revealed that treatment with PCSK9 inhibitors has beneficial effects in lowering LDL-C via inhibition of LDL-receptors (LDL-R), an antiviral effect on HCV infection via down-regulating the surface expression of LDL-R and CD81 on hepatic cells, and a positive association with increased inflammatory responses, as well as with septic shock by down-regulation of hepatocyte LDL-R. On the other hand, PCSK9 inhibition by therapeutic fully humanized antibodies has positive effects in reducing elevated LDL-C. However, their safety and tolerability is an important issue which has to be taken into consideration.",
keywords = "Cholesterol, Hepatitis C virus, Infection, LDL receptor, PCSK9",
author = "Farzad Khademi and Momtazi-borojeni, {Amir Abbas} and Željko Reiner and Maciej Banach and Al-Rasadi, {Khalid Al} and Amirhossein Sahebkar",
year = "2017",
doi = "10.1002/jcp.26040",
language = "English",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - PCSK9 and infection

T2 - A potentially useful or dangerous association?

AU - Khademi, Farzad

AU - Momtazi-borojeni, Amir Abbas

AU - Reiner, Željko

AU - Banach, Maciej

AU - Al-Rasadi, Khalid Al

AU - Sahebkar, Amirhossein

PY - 2017

Y1 - 2017

N2 - Elevated plasma low-density lipoprotein-cholesterol (LDL-C) concentration is the most important risk factor for atherosclerotic cardiovascular diseases (CVDs). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ubiquitously expressed serine proteinase which plays a key role in cholesterol metabolism, but has been found to be implicated in some other lipid-independent physiological processes. In this review, the role of PCSK9 was evaluated not only concerning lipid metabolism but also hepatitis C virus (HCV) infection, bacterial infections/sepsis, and septic shock. Collected data from clinical trials revealed that treatment with PCSK9 inhibitors has beneficial effects in lowering LDL-C via inhibition of LDL-receptors (LDL-R), an antiviral effect on HCV infection via down-regulating the surface expression of LDL-R and CD81 on hepatic cells, and a positive association with increased inflammatory responses, as well as with septic shock by down-regulation of hepatocyte LDL-R. On the other hand, PCSK9 inhibition by therapeutic fully humanized antibodies has positive effects in reducing elevated LDL-C. However, their safety and tolerability is an important issue which has to be taken into consideration.

AB - Elevated plasma low-density lipoprotein-cholesterol (LDL-C) concentration is the most important risk factor for atherosclerotic cardiovascular diseases (CVDs). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ubiquitously expressed serine proteinase which plays a key role in cholesterol metabolism, but has been found to be implicated in some other lipid-independent physiological processes. In this review, the role of PCSK9 was evaluated not only concerning lipid metabolism but also hepatitis C virus (HCV) infection, bacterial infections/sepsis, and septic shock. Collected data from clinical trials revealed that treatment with PCSK9 inhibitors has beneficial effects in lowering LDL-C via inhibition of LDL-receptors (LDL-R), an antiviral effect on HCV infection via down-regulating the surface expression of LDL-R and CD81 on hepatic cells, and a positive association with increased inflammatory responses, as well as with septic shock by down-regulation of hepatocyte LDL-R. On the other hand, PCSK9 inhibition by therapeutic fully humanized antibodies has positive effects in reducing elevated LDL-C. However, their safety and tolerability is an important issue which has to be taken into consideration.

KW - Cholesterol

KW - Hepatitis C virus

KW - Infection

KW - LDL receptor

KW - PCSK9

UR - http://www.scopus.com/inward/record.url?scp=85021828936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021828936&partnerID=8YFLogxK

U2 - 10.1002/jcp.26040

DO - 10.1002/jcp.26040

M3 - Article

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

ER -